Literature DB >> 27492867

Bariatric Radioembolization: A Pilot Study on Technical Feasibility and Safety in a Porcine Model.

Alexander S Pasciak1, Austin C Bourgeois2, Ben E Paxton3, Laurentia Nodit4, Patricia N Coan5, Dara Kraitchman6, Sandra S Stinnett7, Vijay M Patel4, Yingli Fu6, Joleen K Adams5, M Katherine Tolbert8, Cassie N Lux8, Aravind Arepally9, Yong C Bradley10.   

Abstract

PURPOSE: To evaluate feasibility of left gastric artery (LGA) yttrium-90 ((90)Y) radioembolization as potential treatment for obesity in a porcine model.
MATERIALS AND METHODS: This study included 8 young female pigs (12-13 weeks, 21.8-28.1 kg). Six animals received infusions of (90)Y resin microspheres (46.3-105.1 MBq) into the main LGA and the gastric artery arising from the splenic artery. Animal weight and serum ghrelin were measured before treatment and weekly thereafter. Animals were euthanized 69-74 days after treatment, and histologic analyses of mucosal integrity and ghrelin immunoreactive cell density were performed.
RESULTS: Superficial mucosal ulcerations < 3.0 cm(2) were noted in 5 of 6 treated animals. Ghrelin immunoreactive cell density was significantly lower in treated versus untreated animals in the stomach fundus (13.5 vs 34.8, P < .05) and stomach body (11.2 vs 19.8, P < .05). Treated animals gained less weight than untreated animals over the study duration (40.2 kg ± 5.4 vs 54.7 kg ± 6.5, P = .053). Average fundic parietal area (165 cm(2) vs 282 cm(2), P = .067) and average stomach weight (297.2 g vs 397.0 g, P = .067) were decreased in treated versus untreated animals. Trichrome staining revealed significantly more fibrosis in treatment animals compared with control animals (13.0 vs 8.6, P < .05). No significant differences were identified in plasma ghrelin concentrations (P = .24).
CONCLUSIONS: LGA (90)Y radioembolization is promising as a potential treatment for obesity. A larger preclinical study is needed to evaluate the safety and efficacy of this procedure further.
Copyright © 2016 SIR. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27492867     DOI: 10.1016/j.jvir.2016.05.020

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  6 in total

Review 1.  Bariatric Arterial Embolization for Obesity: A Review of Early Clinical Evidence.

Authors:  Bin-Yan Zhong; Godwin Abiola; Clifford R Weiss
Journal:  Cardiovasc Intervent Radiol       Date:  2018-06-05       Impact factor: 2.740

2.  Analysis of weight changes after left gastric artery embolization in a cancer-naive population.

Authors:  David J Kim; Hari S Raman; Amber Salter; Raja Ramaswamy; Andrew J Gunn; Clifford R Weiss; Olaguoke Akinwande
Journal:  Diagn Interv Radiol       Date:  2018 Mar-Apr       Impact factor: 2.630

3.  Left gastric artery embolization for obesity treatment: a systematic review and meta-analysis of human and animal studies.

Authors:  Malkhaz Mizandari; Pedram Keshavarz; Tamta Azrumelashvili; Fereshteh Yazdanpanah; Elnaz Lorzadeh; Hamidreza Hosseinpour; Amir Bazyar; Seyed Faraz Nejati; Faranak Ebrahimian Sadabad
Journal:  Abdom Radiol (NY)       Date:  2021-04-07

Review 4.  Weight Loss and Gastrointestinal Hormone Variation Caused by Gastric Artery Embolization: An Updated Analysis Study.

Authors:  Yi Tang; Xiaohui Pan; Ge Peng; Nanwei Tong
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-16       Impact factor: 5.555

Review 5.  Rationale and Preclinical Data Supporting Bariatric Arterial Embolization.

Authors:  Yingli Fu; Dara L Kraitchman
Journal:  Tech Vasc Interv Radiol       Date:  2020-01-11

6.  Bariatric Arterial Embolization with Calibrated Radiopaque Microspheres and an Antireflux Catheter Suppresses Weight Gain and Appetite-Stimulating Hormones in Swine.

Authors:  Clifford R Weiss; Yingli Fu; Cyrus Beh; Charles Hu; Dorota Kedziorek; Eun-Ji Shin; Robert A Anders; Aravind Arepally; Dara L Kraitchman
Journal:  J Vasc Interv Radiol       Date:  2020-08-14       Impact factor: 3.464

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.